A new illustrated review published in the journal Research and Practice in Thrombosis and Haemostasis makes the case that many established reference intervals (RIs) used to interpret the results of laboratory tests are biased and highly problematic…
Dear Valued Partners, Recently Dr. Len Valentino, President and CEO of the National Hemophilia Foundation, announced his retirement at the end of 2023 and the search for a new leader has begun. Under Dr. Valentino’s leadership, NHF has taken…
The BDRC (formerly the NRB) is organized to enable people affected by inherited bleeding disorders and their loved ones – recognized as lived experience experts (LEEs) – to actively participate and influence the direction of transformational…
CSL Behring has announced that the first patient has been dosed with HEMGENIX®, the only hemophilia B gene therapy product currently approved in the U.S.
Approved by the U.S. Food and Drug Administration in November 2022, HEMGENIX is indicated…
Earlier this month The American Society of Clinical Oncology (ASCO) held their annual meeting in Chicago, IL. The opening session presentation was delivered by ASCO President Eric P. Winer, MD, FASCO, a dedicated clinical oncologist for more than 30…
NBDF History In 1948, the foundation got its start as simply “The Hemophilia Foundation” – then in 1956, the foundation formally incorporated into what is known today as – the National Hemophilia Foundation. Even then, it was…
#block-recentonlineeducation {
display:none;
}
Clotting Cascade 3D VideoCome along on a 3D adventure in this video about how blood clots when there is a bleed or injury. The 3D animation in this video shows each of the proteins (called clotting…
The U.S. Food and Drug Administration (FDA) has approved BioMarin’s ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy product for the treatment of adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 (AAV5…
Sanofi recently shared positive data from the Phase 3 XTEND-Kids study, which is currently evaluating once weekly prophylaxis with ALTUVIIIO™ in previously treated patients younger than 12 years of age with severe hemophilia A.ALTUVIIIO is Sanofi’s…